Bioventus Inc. (BVS) Stock Score, Valuation & Financial Research
Bioventus Inc. is in the Healthcare sector and Medical - Devices industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 33/100.
Quick answer for BVS
Bioventus Inc. currently has a Wall Street Score of 33/100. The stored market price is $12.98. Its financial score is 24/100. Its valuation score is 22/100. The latest WSS change is -0.1 points. These figures are a research snapshot, not a buy or sell recommendation.
What Bioventus Inc. does
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company’s product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other orga
BVS financial snapshot
- Wall Street Score:
- 33/100
- Current price:
- $12.98
- Market capitalization:
- $879.4M
- Revenue:
- $581.8M
- Net income:
- $54.5M
- Free cash flow:
- $71.4M
- Cash:
- $29.5M
- Total debt:
- $263.7M
- EPS:
- 0.80
- P/E ratio:
- 16.2x
- Financial score:
- 24/100
- Valuation score:
- 22/100
- Revenue score:
- 22/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $71.4M, showing positive cash generation.
- The balance sheet shows $29.5M of cash versus $263.7M of total debt, so leverage deserves attention.
- The latest Wall Street Score change is -0.1 points: BVS decreased 0.1 points because some fundamentals weakened.
What the numbers mean
Its current valuation score is 22/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 24/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-09.
How to research BVS
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.